UF/IFAS, Florida Strawberry Industry, and Ohalo Join Forces to Combat Devastating Fungal Disease
APTOS, Calif., Dec. 20, 2024 /PRNewswire/ -- Ohalo Genetics, Inc. has entered into a groundbreaking Development & Commercialization Agreement with...
Year: 2024
Zimmer Biomet to Present at the 43rd Annual J.P. Morgan Healthcare Conference
WARSAW, Ind., Dec. 20, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced that members of the...
Quantum Biopharma Diversifies Treasury With the Purchase of USD $1,000,000 of Bitcoin (BTC) and Other Cryptocurrencies and to Allow for Future Financings and Other Transactions in Cryptocurrency
TORONTO, ON / ACCESSWIRE / December 20, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), is pleased...
American Health Imaging Brings State-of-Art Medical Imaging to the Greater Huntsville Area
Two New Outpatient MRI & CT Centers are Now Open in Huntsville and Madison, Alabama HUNTSVILLE, ALABAMA / ACCESSWIRE /...
Top Healthcare IT Vendors Driving Interoperability and Transforming Care Delivery in Brazil, India, Singapore, South Africa, and Italy: Black Book Research
TAMPA, FLORIDA / ACCESSWIRE / December 20, 2024 / Black Book Research, a leading healthcare IT market research firm, has...
Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants
WILMETTE, Ill., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar” or the “Company”), a clinical-stage biotechnology...
Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine
FREEHOLD, N.J., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, (“Channel” or the “Company”), (NYSE American: CHRO), a pioneer...
BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points
SAN DIEGO, Dec. 20, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company (“BioAtla” or the...
Renovaro Enters into a Strategic Collaboration with Nebul to Advance a Paradigm Shift for Early Disease Detection
Renovaro will Establish the GEDi CUBE Next Generation Nvidia Blackwell Cluster with Nebul's certified AI Healthcare Cloud solutions LOS ANGELES,...
HWH International Inc. and Sharing Services Global Corporation see opportunity in Robotics
BETHESDA, MD, Dec. 20, 2024 (GLOBE NEWSWIRE) -- HWH International Inc. (“HWH”) (Nasdaq: HWH) and its partner Sharing Services Global...
Light-it Group Launches Enlighten Ventures: A Micro-VC Initiative to Propel Healthtech Innovation
Javier Lempert (CTO & Founder), Alan Brande (CEO & Founder) and Martin Oppenheimer (COO & Founder) at Light-it’s HQ. AVENTURA,...
IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank
Funds expected to be used to advance IO Biotech’s immune-modulating therapeutic cancer vaccines, including potential BLA submission for IO102-IO103 in...
Alignment Healthcare to Present at the 43rd Annual J.P. Morgan Healthcare Conference
ORANGE, Calif. , Dec. 20, 2024 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), today announced that it will present...
Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia
FOSTER CITY, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical...
Commure Acquires Memora Health, a Digital Care Navigation Platform, to Enhance Intelligent Care Navigation
MOUNTAIN VIEW, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Commure, a leading healthcare technology company, announced today the acquisition of...
RAD 202 Receives Approval to Start Phase 1 Therapeutic Trial
Ethics approval received in Australia for the initiation of RAD’s Phase 1 therapeutic trial of 177Lu-RAD202 in Breast and Gastric...
Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASH
In the pre-specified per-protocol population, belapectin showed a statistically significant reduction (p-value < 0.05) in development of esophageal varices in...
Altamira Therapeutics Announces Transition from NASDAQ to OTC Markets
HAMILTON, BERMUDA, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Trading to continue under ticker symbol “CYTOF”No reverse stock split planned Altamira...
Sernova Reschedules its Annual General and Special Meeting of Shareholders to January 10, 2025
LONDON, Ontario and BOSTON, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading...
NervGen Announces “At-The-Market” Equity Program
Vancouver, British Columbia--(Newsfile Corp. - December 20, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a...